Biofarm S.A (BIO) Fair Value & Analysis
Healthcare · RO · Market cap 349M PLN
Fair value as of: Jun 24, 2026
From 25 valuation models · updated 5 days ago
Share price −5.0% over the past month.
Price vs Fair Value (12 months)
12‑month range 3.62 PLN – 4.50 PLN · fair‑value band 1.17 PLN – 2.38 PLN · the 3.85 PLN price screens above the 1.74 PLN fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Biofarm S.A (BIO) currently trades at 3.85 PLN, while our model-based Fair Value estimate is 1.74 PLN — implying the stock looks roughly 54.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Biofarm S.A generated revenue of 283M PLN at a net margin of 1.2%. Revenue declined 17.1% year over year. It earns a return on equity of 0.6%. Net debt stands at 31.1M PLN. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescription medicines, food supplements, medical devices, cosmetics, medical devices, and other products. The company also exports its products in Albania, Azerbaijan, Georgia, Jordan, Iraq, Kyrgyzstan, Malta, Republic of Moldova, Serbia, and Hungary. Biofarm S.A. was incorporated in 1921 and is based in Bucharest, Romania.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Biofarm S.A reported revenue of 283M PLN in FY2025 versus 163M PLN in FY2021, a compound +14.7%/yr. Reported net income was 3.4M PLN in FY2025, compounding +4.2%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $288.18 | $51.70 | -82% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Biofarm S.A (BIO) undervalued?
What is the fair value of BIO?
What is the quality score of BIO?
What is the revenue of Biofarm S.A (BIO)?
What is the net profit margin of BIO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.